† These authors contributed equally.
Academic Editor: Peter A. McCullough
We evaluated the lipidomic profile of patients with very high-risk
atherosclerotic cardiovascular disease (ASCVD) by ultra-performance liquid
chromatography-quadrupole time-of-flight mass spectrometry (UPLC-MS). A total of
64 patients with a very high risk of ASCVD were recruited and randomLy divided
into the atorvastatin group (20 mg, every night, 4 weeks) or the combined group
(evolocumab, 140 mg, once every 2 weeks on top of atorvastatin (20 mg per day)).
The level of serum lipids was detected before and after treatment for 4 weeks.
The lipid classes of triacylglycerols, cholesteryl esters, and sphingomyelins
were analyzed using an ultra-performance liquid chromatography-quadrupole
time-of-flight mass spectrometry system. There were 32 patients in each group.
After 4 weeks of treatment, the levels of total cholesterol (TC) and low-density
lipoprotein cholesterol (LDL-C) in both groups and the level of lipoprotein-a
(Lp-a) in the combined group were lower. In the combined treatment group, the
levels of TC, LDL-C, and Lp-a decreased significantly (P